All posts by imreal

Mashup Media, LLC Announces Relaunch of GU Oncology Now


Mashup Media, LLC, a publisher of medical news platforms, is proud to announce the official relaunch of its genitourinary (GU)-focused oncology platform, GU Oncology Now. The relaunch includes new branding, expanded partnerships, and an enhanced digital platform that will provide key content from experts in urology, oncology, nuclear medicine, and more. A redesigned website—with enhanced and more intuitive navigation—an updated print publication, and more comprehensive access to key opinion leaders also will be included.

GU Oncology Now delivers the latest news in therapeutics, clinical trials, and conference coverage, highlighting important advancements in GU oncology treatments and technologies with the goal of better informing oncology decisions and improving patient outcomes.

GU Oncology Now is backed by leaders in the field, including the platform’s Editor-in-Chief, Catherine H. Marshall, MD, MPH, assistant professor of oncology in the Department of Oncology, Division of Genitourinary Cancer, at the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Editor Jérémie Calais, MD, MSc, director of the theranostics and clinical research programs, Ahmanson Translational Theranostics Division, and associate professor in the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles. “We are learning so much more about the biology of cancer, and it is leading to exciting new changes. The management of patients with genitourinary cancer is very complex—from new treatments to innovations in survivorship care—and it is important to stay connected with the changes,” said Dr. Marshall.

Additional key contributors include the platform’s associate editors, David Ambinder, MD, and Akhil Abraham Saji, MD, urology residents at New York Medical College/Westchester Medical Center.

The new GU Oncology Now features interviews and videos from experts and provides innovative cancer research and practice updates. In addition to its website, a monthly publication highlights original articles and leverages the best insights from leaders in the field. The brand also regularly deploys valuable content via weekly email newsletters and through active and timely conversations on its social media platforms.

GU Oncology Now exclusively partners with The Uromigos to prominently feature podcasts hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, international thought leaders in GU oncology. Each episode of The Uromigos podcast dives into the latest data and clinical news relevant to the care of GU oncology patients and features fascinating discussions with leading experts from around the world. In addition, The Uromigos podcast and GU Oncology Now’s parent company, Mashup Media, will launch their first live meeting in the GU oncology space in Nashville, Tennessee, September 30 through October 1. The Uromigos Live & Unplugged will convene the best minds in GU oncology to discuss clinically impactful topics.

Courtney Leonard, Vice President of Operations, Mashup Media, remarked, “the relaunch of GU Oncology Now falls at the perfect time, as we’re introducing our first GU oncology conference in partnership with The Uromigos. We will cover this intimate yet powerful event on our new GU Oncology Now website and updated email and social media platforms, as well as in our highly regarded print publication.”

Visit guoncologynow.com to learn more, sign up for our email newsletters, and follow us on social media.

About Mashup Media, LLC

Mashup Media, based in Manalapan, New Jersey, is a multimedia publishing company passionate about providing health care professionals with a platform to further publicize their work. Driven by data and analytics, Mashup Media produces cutting-edge products that deliver content from trusted sources and industry thought leadership. To learn more, visit mashupmediallc.com.

About GU Oncology Now

GU Oncology Now is a robust platform that delivers current genitourinary oncology-specific news, with the goal of informing oncology decisions and improving patient outcomes. The website highlights essential clinical content, providing health care professionals with the opportunity to evaluate the latest clinical trials, cutting-edge research, and case studies. Other key features include conference coverage, roundtable discussions, and access to The Uromigos podcast. In addition to its powerful website, GU Oncology Now produces a monthly publication highlighting original articles and leverages email and social media to highlight the best insights from key opinion leaders in the field.

About The Uromigos

Drs. Thomas Powles and Brian Rini are international thought leaders in genitourinary oncology. Each episode of their podcast delves into the latest data and clinical news relevant to the care of GU oncology patients. Join them for fascinating discussions with leading experts from around the world on these topics and more.

Share article on social media or email:

Board Certified Internal Medicine Specialist, Dr. Manish P. Luhana Named NJ Top Doc


Dr. Manish P. Luhana

Dr. Manish P. Luhana

I believe Preventive Medicine is the best medicine.

Dr. Manish P. Luhana has been reviewed and approved by NJ Top Docs for 2022. Dr. Luhana is board certified by the American Board of Internal Medicine and has been practicing in Morris County for over a decade.

“I believe Preventive medicine is the best medicine,” says Dr. Luhana.

Dr. Luhana is currently affiliated with Chilton Medical Center and Morristown Medical Center, a part of Atlantic Health System as well as St. Clare’s Denville Hospital, a part of Prime Health Care. Dr. Luhana is also the Medical Director at Lincoln Park Care Center located in Lincoln Park, New Jersey.

Additionally, Dr. Luhana is an Attending Physician at Resort at JDT, Villa at JDT, and Care One Parsippany.

Dr. Luhana is fluent in Hindi and Gujrati.

To learn more about this reviewed and approved NJ Top Doc, please visit: https://njtopdocs.com/nj-doctors/drmanishluhana/

—

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



Glenna Sosi’s newly released “I Am Is Not Sick” is an encouraging message of one’s connection to God and the power of prayer


News Image

“I Am Is Not Sick”: a motivating discussion of scripture. “I Am Is Not Sick” is the creation of published author Glenna Sosi.

Sosi shares, “in the course of writing this book, the Lord reminded me that he is the great I am, and he is never sick and that we are his children called by his name.

“We are heirs and joint heirs with Christ Jesus, created in his image and his likeness, and as his children, we have authority and dominion over sickness and disease.

“Jesus took care of the sin nature on the cross when he cried; it is finished, therefore we also have that authority to speak healing and health to our bodies

“Remember God’s word is covenant words, so when you speak it, you are praying the answers.”

Published by Christian Faith Publishing, Glenna Sosi’s new book brings a powerful message of the impactful nature of prayer and how one uses their words in relation to their physical and spiritual selves.

Sosi shares in hopes of aiding others in deepening their understanding of God’s word and the empowering resource found within prayer.

Consumers can purchase “I Am Is Not Sick” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “I Am Is Not Sick,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Eye-Opening Answers to Questions About Life, Faith and the Bible


News Image

For many years I have longed to write what I believe God has placed on my heart. Through the growth of my spirit, my new pastor and the endless questions my children ask me, I knew it was time to pen what God had given me to say.

Author Tiffany Potter shares her views on the Pentecost with readers in A Personal Depiction: God’s Call to Build a Stronger Generation ($14.49, paperback, 9781662858277; $6.99, e-book, 9781662858284).

In her book, Potter shares the insightful, personal thoughts from her mind with readers. This includes the truths that she believes God has given her to share. By sharing her life and how she learned to view the world and religion, she hopes to help others understand Pentecost better and the ideas of ‘one’ God, ‘one’ faith and ‘one’ baptism. Her goals are to put the ideas of God into her own words and explain Him the way she sees and understands Him.

“This book was written from the inspiration of my spiritual walk with God,” said Potter. “For many years I have longed to write what I believe God has placed on my heart. Through the growth of my spirit, my new pastor and the endless questions my children ask me, I knew it was time to pen what God had given me to say.”

Tiffany Potter was born in Alabama and raised in Mississippi. She has a degree in chemistry and a second degree in medical laboratory science. Potter has always been a part of the Bible Belt with an upbringing full of Christianity. She learned that there is more to being a Christian than going to church and looking the part. Growing up Pentecostal, she was never forced to follow in her parent’s footsteps. It was through personal endeavors and personal research that she learned to know God the way she does. This book is her gift to Him for all He has given to her. Potter enjoys spending time with her family—four boys take much of her time and extra love. Her passion outside of church is food. She cooks anything from scratch that she can, including baking. Beyond work and family, her time is spent with the Lord.

###

Xulon Press, a division of Salem Media Group, is the world’s largest Christian self-publisher, with more than 15,000 titles published to date. A Personal Depiction: God’s Call to Build a Stronger Generation is available online through xulonpress.com/bookstore, amazon.com, and barnesandnoble.com.

Share article on social media or email:

Aktiv Pharma Group to Participate in the FDA Emerging Technology Program


Aktiv Pharma Group (Aktiv) announced today the acceptance of its novel glass-free, film-based flexible primary drug container (PDC) technology for sterile injectables named ARCH, into the US Food and Drug Administration (FDA) Emerging Technology Program (ETP). The ETP is a collaborative effort which supports the FDA’s mission to facilitate modernization in the pharmaceutical industry and helps pharmaceutical companies reduce the time and cost requirements of introducing new, innovative solutions.

The ETP will enable the FDA to establish better understanding of the unique aspects of film-based PDCs and use this insight to develop guidelines and regulations ahead of a broader adoption by the industry. It will also allow Aktiv to communicate with the FDA to create alignment on regulatory, technical, and scientific matters associated with gaining regulatory approvals for Aktiv’s products. “We are excited to participate in this important program and delighted that our technology was recognized by the Agency for its broad potential to improve quality and safety of sterile injectable products” said Patricia Brown, Aktiv’s VP of Quality and Regulatory.

ARCH uses high-barrier polymer films to provide superior performance and increased functionality over conventional glass packaging, either as substitute to vials or when incorporated into prefilled drug delivery systems. ARCH was developed by Aktiv to address potential interactions between biologics and glass-based containers, improve aseptic barriers, provide a superior solution for drugs that require reconstitution at the time of use, and create a foundation for more functional and user-friendly combination products.

The first products to feature the flexible ARCH containers are emergency-use autoinjectors currently being advanced to FDA approval. Aktiv’s autoinjector pipeline includes tranexamic acid (TXA), atropine, pralidoxime chloride (2-PAM), atropine/2-PAM dual-injection, and scopolamine. The flexible container is crucial for achieving the unprecedented ruggedness and reliability of the ARAI autoinjector platform. Aktiv is additionally developing a biologic combination product in collaboration with a leading biopharmaceutical company and planning new products with integrated reconstitution capability.

About Aktiv’s Emerging Technology

With the exception of ampules, conventional rigid containers necessitate drug contact materials other than glass, most commonly rubber in elastomeric stoppers/plungers. In prefilled syringes and autoinjectors, interior container walls are frequently coated with silicone to prevent plunger binding and to improve glide. These materials are especially problematic for biopharmaceuticals which are inherently unstable and prone to aggregation and adsorption. Headspace in rigid containers results in a liquid/gas interface that further reduces stability of biopharmaceutical products. By comparison, Aktiv’s flexible film containers do not rely on elastomeric stoppers or siliconized surfaces, reducing the number of drug contact materials to just one, and their headspace can be minimized or even eliminated. Instead of stoppers, Aktiv’s containers utilize permanent, physicochemically bonded film-film closure, which unlike physically mated closures maintains aseptic barrier integrity even at cryogenic temperatures.

One of the key features of Aktiv’s technology is that the flexible containers can be configured with multiple compartments to be merged at the time of use by peeling frangible seals separating them, which enables incorporating aseptic reconstitution/mixing capability into the container itself. This reduces the room for potential user errors and contamination associated with the practice of packaging lyophilized drugs and their diluents into separate vials. It also allows for significantly easier implementation of automated reconstitution/mixing in drug delivery devices.

About Aktiv’s ARAI Autoinjector Platform

The ARAI autoinjector has been developed by Aktiv as a next generation autoinjector platform to address the shortfalls of previous autoinjectors by improving usability, reliability, robustness, and drug stability. ARAI is a versatile platform that can deliver up to 5 ml dose volumes, perform intramuscular and subcutaneous injections, perform simultaneous injections of multiple separately contained drugs, and automatically reconstitute drugs formulated in dry form. Aktiv is currently expanding the ARAI platform to include a consumer market autoinjector for biologics that will feature the same reliability, robustness, and usability benefits in a smaller form factor and with added data connectivity.

About Aktiv

Aktiv is a vertically integrated specialty pharmaceutical company with combination products contract development and manufacturing organization (CDMO) capabilities, that is developing, manufacturing, and commercializing sterile injectable products in a portfolio of proprietary, value-added, glass-free prefilled delivery systems.

Aktiv continues establishing itself as a vertically integrated CDMO with unique combination product competencies specifically targeting biopharmaceuticals. The company’s facilities in Colorado include device development, chemistry, manufacturing and controls (CMC), and manufacturing equipment labs, as well as assembly rooms and sterile fill-finish suites operated under Good Manufacturing Practice (GMP).

Share article on social media or email:

Maryland Resident Wins 2022 Caregiver of the Year Award


The Home Care Association of America (HCAOA) announced last week that Katrice Turner, employed as a caregiver for Absolute Companion Care in Monkton, Maryland, has been named the 2022 Caregiver of the Year. Turner was chosen from more than 300 nominated caregivers from nearly all 50 states. The award came with a $1,000 cash prize, and Turner was recognized at a special ceremony on Sunday, September 18, 2022, during the HCAOA Annual Leadership Conference in Orlando.

Turner’s nomination by Absolute Companion Care Executive Director Kathryn C. Rogers, M.Ed., painted a moving picture of Turner’s journey with the organization. Within a year of joining the agency in 2009, Turner’s resourcefulness, attentiveness, empathy, and leadership propelled her career growth within the company as she rose to Team Lead for an entire 24/7 caregiving team.

“Katrice is resourceful, attentive, empathetic, and adaptive. Her dependability knows no bounds, she never misses a shift, never lets her standards down, and never accepts less than those standards from others on her team. She has built a level of trust with clients, their family members, and her team members that is truly admirable,” said Rogers.

Turner’s anticipation of needs and problem-solving have also greatly benefited her clients, Rogers noted. “She took a post-stroke client with severe depression from not wanting to leave her home to getting beautifully dressed, fully made-up, and [going] out into the community to enjoy social activities every week,” said Rogers. “Then, when that client’s husband began showing signs of dementia, Katrice was the first to notice immediately and alerted the agency and the family, helping this couple to stay together and age gracefully,” Rogers added.

“What makes Katrice exemplary is her dedication to her employer and the career path she has created at her agency,” said Vicki Hoak, CEO of the HCAOA, “When home care agencies are facing a critical workforce shortage and being forced to turn clients away because they don’t have enough caregivers, it is remarkably inspiring to recognize someone who is not only committed to providing care to those who need it in their homes but also has grown and evolved with the same agency for more than ten years.”

# # #

About Absolute Companion Care

As part of the Briggs Home Care family, Absolute Companion Care offers the highest quality care, training, and professionalism, decreasing hospitalizations and emergency room visits and improving client health and wellness outcomes. For more information, please visit https://absolutecompanion.com/ or call 410-357-9640.

Share article on social media or email:

NarcX Awarded New Patent for Immediate On-site Medication Disposal, Broadening the Company’s Large-Scale Efforts to Reduce the Use of Unused Medications


News Image

“This revolutionary drug disposal solution helps hospitals, pharmacies, law enforcement agencies, and people at home dispose of their unused medication or potentially harmful narcotics safely,” says NarcX Co-Founder and Principal Gavin Collier.

NarcX, a Utah-based company that eliminates the diversion of medications and frequently abused controlled substances, has been awarded US Patent No. 11,446,531 by the USPTO for its medication disposal solution. The company’s patented technology is an environmentally safe, liquid-based solution that immediately renders prescription drugs non-divertible and ultimately non-retrievable in two hours or less. NarcX meets the Drug Enforcement Administration’s (DEA) strict definition of non-retrievable. This expedient process eliminates the need for incineration; therefore, eliminating the possibility for diversion. The announcement comes as the nation grapples with an opioid epidemic that shows no signs of slowing down.

“As many are aware, we’ve had a major opioid problem in the U.S.,” says NarcX Co-Founder and Principal Gavin Collier, “this revolutionary drug disposal solution helps hospitals, pharmacies, law enforcement agencies, and people at home dispose of their unused medication or potentially harmful narcotics safely. This patent will continue our large-scale efforts to combat an epidemic that has already affected too many lives.”

Where it All Began

When the patented technology was originally hypothesized, Collier, along with fellow inventor, entrepreneur and Co-Founder Jordan Erskine, discovered that pharmacies, hospitals, and medical providers had difficulties adopting proper drug disposal methods, primarily due to high costs and complex procedures. In response, NarcX was created and is the first and only independently validated method of on-site destruction for prescription drugs in the United States.

Teaming up with fellow inventors, CEO David Schiller and Co-Founder Christian Kasteler, their revolutionary solution quickly found its way into hospitals, pharmacies, and drug enforcement facilities as a compliant, practical, and cost-effective way to prevent the diversion of unused medications.

From DEA to Families at Home

While this is the only patent held exclusively by NarcX, it will be a game changer in the fight against drug diversion and abuse. The patented technology is already used by law enforcement agencies and healthcare facilities across the country. With this newly-awarded patent, the solution will now be available to people at home who need a safe method to dispose of their unwanted and unused prescription medications.

Convenient and Low-Cost Solutions

“Most conventional drug disposal methods such as collection bins require stockpiling, incineration, are highly susceptible to diversion, and are much more costly” said Co-Founder David Schiller who is now CEO of NarcX, “now, we can offer everyday Americans a convenient and simple disposal method for their unused medications.”

Schiller’s many years on the frontlines of the opioid epidemic helped shape the primary purpose and structure of the company. “When I was with the DEA, I saw firsthand the devastation that unused and diverted prescription medications can cause. Since 1999, roughly 1 million drug overdose deaths have occurred in the U.S.”

Schiller reflected on a grim scenario that has only worsened in the past few months. “According to the Centers for Disease Control, over 107,000 Americans have died from a drug overdose in just the past 12 months. With cases rising so dramatically, I am proud to represent a company that could make a real difference in bringing those numbers down.”

NarcX is now partnering with select pharmacies and government agencies to bring its convenient and low-cost solutions directly to families across the country.

For questions, comments, and more, please contact David Schiller at mailto:david@narcx.com [david@narcx.com __title__ null]

If you have unwanted or unused medications, please visit our website at http://www.narcx.com to find out more.

Thank you for helping us keep our communities safe!

– NarcX Team

Related Links:

U.S. Patent and Trademark Office

NarcX Press Release 02.21.2018

NarcX

Centers for Disease Control and Prevention

NPR: More than a million Americans have died from overdoses during the opioid epidemic

AMA: Nation’s drug-related overdose and death epidemic continues to worsen

Share article on social media or email:

New Vitae Wellness and Recovery’s Katie Pintabone-Brown and Keegan Hackman Named Lehigh Valley Business 2022 Forty Under 40 Honorees


Keegan Hackman and Katie Pintabone-Brown

“We congratulate Katie and Keegan on the exciting honor of being named to Lehigh Valley Business’s Forty Under 40 list,” said New Vitae President and CEO Judith O. Yanacek. “Their inspiring leadership has been a tremendous benefit to New Vitae.”

Lehigh Valley Business has selected Quakertown House Administrator Katie Pintabone-Brown and Recovery Center Director Keegan Hackman as recipients of its Forty Under 40 Awards. These awards recognize Lehigh Valley leaders under the age of 40 based on their professional accomplishments, community service and commitment to inspiring change. Winners are selected by an outside panel of judges that includes previous winners.

“We congratulate Katie and Keegan on the exciting honor of being named to Lehigh Valley Business’s Forty Under 40 list,” said New Vitae President and CEO Judith O. Yanacek. “Their inspiring leadership has been a tremendous benefit to New Vitae, and we are grateful for their constant dedication to the well-being and care of our residents. They are very deserving of this recognition, and we celebrate their invaluable contributions to the New Vitae community.”

Pintabone-Brown oversees New Vitae’s Quakertown House, a licensed Personal Care Home that encourages increased independence by connecting residents with the community and has been with New Vitae for 17 years. As administrator, she works to ensure the facility is a welcoming place to live, work, and visit. She is a certified Personal Care Home Administrator and holds a bachelor’s degree in psychology from Kutztown University.

“I am honored to be included among other Lehigh Valley leaders working to make our community a better place, and to share this honor with my colleague, Keegan,” said Pintabone-Brown. “I am grateful for the opportunity to serve New Vitae’s residents and ensure that they have a safe, and nurturing environment to focus on their well-being and recovery.”

Hackman joined New Vitae Wellness and Recovery in 2018 as an outpatient therapist. In 2019 she became the Clinical Supervisor and currently serves as the Director of outpatient services at The Recovery Center. A Licensed Clinical Social Worker, she received a master’s degree in social work from Delaware State University and a bachelor’s degree in psychology from the University of Delaware.

“It is a wonderful honor to be recognized by Lehigh Valley Business for my work with New Vitae,” said Hackman. “I am proud to support our residents in their growth and recovery through our holistic programs and services, and I am grateful to be included in this list alongside other inspiring community leaders, including my colleague, Katie.”

Pintabone-Brown and Hackman were honored on September 14 during an awards celebration at DeSales University. Read the list of Lehigh Valley Business Forty Under 40 winners.

About New Vitae Wellness and Recovery: New Vitae Wellness and Recovery is dedicated to providing comprehensive behavioral health care services and supportive residential opportunities for adults. Our array of services promotes holistic wellness through varying levels of residential supports that are combined with clinical services for individuals who experience mental health, addiction, brain injury, and intellectual disability challenges. With sites in Bucks, Lehigh, and Philadelphia counties, New Vitae works with individuals and families to utilize personal strengths, develop personal independence, and provide opportunities for community connections. To learn more about our services, please visit http://www.newvitaewellness.com.

Share article on social media or email:

Emergency Medicine Expert Dr. Yaritza Arriaga-O’Neill Joins Exclusive Haute MD Network


Dr. Yaritza Arriaga-O’Neill

Patients appreciate the warm and welcoming approach Dr. Arriaga-O’Neill takes. She never rushes visits, and patient education is part of each interaction.

Yaritza Arriaga-O’Neill, MD, FAAEM, is a highly skilled physician with a passion for delivering top-quality, personalized care. Through her work at Highway Integrative Health Center in Davenport, Florida, Dr. Arriaga O’Neill enjoys helping patients meet their acute care needs, delivering preventive health services, and chronic disease management.

Education has always been a guiding force in Dr. Arriaga-O’Neill’s life. She completed her undergraduate degree at Universidad de Puerto Rico (UPR) in Rio Piedras before moving on to medical school at Universidad Autónoma de Guadalajara (UAG) in Jalisco, Mexico. She then completed a fifth pathway program and emergency medicine training in Puerto Rico. To this day, Dr. Arriaga-O’Neill continues to learn and evolve.

With over a decade of experience, Dr. Arriaga-O’Neill has provided accurate care to adults and pediatrics. Patients appreciate the warm and welcoming approach Dr. Arriaga-O’Neill takes. She never rushes visits, and patient education is part of each interaction. Her goal is to partner with the patient and find the root of their problems. This empowers patients to take an active role in shaping their health and wellness future.

About Highway Integrative Health Center:

Highway Integrative Health Center is unlike other urgent or primary care offices as they offer a wide range of services, including preventative care, IV Therapy, comprehensive physical exams, lab testing, personalized primary care, and to add to the already fabulous mix, Botox.

If you want to look as good as you feel, you are invited to partner with Dr. Arriaga-O’Neill for all of your healthcare and aesthetic needs.

Learn more about Dr. Yaritza Arriaga-O’Neill by visiting:

https://hauteliving.com/hautebeauty/mdmember/dr-yaritza-arriaga-oneill/

ABOUT HAUTE MD NETWORK:

Haute Beauty and Haute MD is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute MD, visit https://hauteliving.com/hautebeauty/mdmember/

Share article on social media or email:

Pregnancy & Newborn’s Survey of More than 3,000 Parents Calls Attention to the Unsustainable Childcare System in the US


News Image

Half of those who responded said they either left a job, changed jobs, or decided to become a stay-at-home parent because of the cost or availability of childcare.

Pregnancy & Newborn, a wholly owned subsidiary of FueledLoop LLC, a division of Aeroflow Healthcare recently conducted a survey of over 3,000 parents on how the accessibility and cost of childcare in the United States have affected their lives and careers—and the results are astounding.

Millions of mothers left the workforce during the height of the pandemic, many never to return. The lack of childcare was the number one reason moms left or changed jobs in 2021. With the average cost of monthly daycare tuition for just one child totaling 22% of a family’s gross annual income, it’s no wonder why many families across the country have decided that returning to the office is not worth the cost.

A number of survey respondents from dual-income homes told Pregnancy & Newborn that even though both parents were working, they were still unable to afford the cost of daycare. And because these families made what is considered to be a large enough income, they were ineligible for government-subsidized programs.

Some of those families surveyed told Pregnancy & Newborn that even when both parents, or in many cases, just one parent in a single-parent household worked and sent their children to daycare, the cost of daycare was more than the cost of housing.

Half of those who responded said they either left a job, changed jobs, or decided to become a stay-at-home parent because of the cost or availability of childcare. A total of 77% of respondents who are not currently working said they would return to the workforce if childcare were more affordable or accessible.

What’s more, Pregnancy & Newborn has found that 80% of survey respondents were on a waitlist of six months or longer, further emphasizing the issue of available childcare; some waitlists exceeded two years, indicating that many parents who wished to return to the workforce were unable to due to the availability of childcare.

For some of those who were able to burden the cost and to get a spot in daycare, childcare centers’ limited hours, or drop-off and pick-up times not aligning with parents’ working hours means that in addition to the substantial cost of childcare, parents are left to supplement the time with extra help (and an additional cost). In fact, 40% of survey respondents said they have to supplement childcare.

With this being a nationwide issue, still, only 9% of employers provide childcare subsidies to their employees. America is facing a recession and a labor shortage, and Pregnancy & Newborn suggests that it’s time we look at the lack of parental support and the looming childcare crisis throughout the country as the real culprits. You can read the full report here.

Pregnancy & Newborn polled 3,087 mothers, parents, and expectant parents, and the results of this survey were analyzed and originally published on September 1, 2022.

Share article on social media or email: